Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
BACKGROUND
Aripiprazole is a new antipsychotic agent that has proven safe and efficacious in controlled clinical trials. However, few published data on its effectiveness and safety when used in augmentation and combination are available.


METHODS
Our study aimed to determine the functional effectiveness and safety of different combinations of aripiprazole with other psychotropics in resistant patients. All acute not selected (15) patients treated with aripiprazole and other psychotropics between February 2005 and May 2007 are included.


RESULTS
Mean follow-up 20.4 days. Main diagnosis was schizophrenia (40%) and mean dose of aripiprazole was 25 mg/d. Resistant patients received initially multiple psychotropics (mean 3.3) and their functional status was very low. A significant functional improvement was observed after admission in most (12) of them. Only three patients experienced mild to moderate improvement; another three patients showed extrapyramidal symptoms. No dermatological reactions or adverse effects were observed with lamotrigine association. DISCUSIONS: The combination of aripiprazole with other psychotropics was well tolerated. No significant new adverse reactions were observed. In a short term follow-up, our results show a good tolerability of aripiprazole in combination with other psychotropics of different groups.
Cobo Gómez
Jesús Vicente
JV
Salut Mental, Corporació Sanitària Parc Taulí. Sabadell, Barcelona, Spain. jcobo@tauli.cat
Gómez
Jesús Vicente Cobo
JV
Fuste
Gideoni
G
Coronas
Ramón
R
Benito
Nagore
N
Barbero
Juan-David
JD
Domenech
Cristina
C
García-Parés
Gemma
G
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068180:Aripiprazole; D004351:Drug Resistance; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D010554:Personality Disorders / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D013030:Spain
D014150:Antipsychotic Agents; D010879:Piperazines; D011619:Psychotropic Drugs; D015363:Quinolones; D000068180:Aripiprazole